Calliditas Therapeutics AB (publ)
CLTEF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $1 |
| % Margin | -14,236.9% | – | – | 90.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -264,513.8% | – | – | -5.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -273,630.5% | – | – | -8.5% |
| EPS | -0.006 | 0 | -0.004 | -0.88 |
| % Growth | – | 100% | 99.5% | – |
| EPS Diluted | -0.006 | 0 | -0.004 | -0.88 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -258,779.1% | – | – | -5.4% |